CeriBell (NASDAQ:CBLL) CRO Joseph Manni Sells 768 Shares

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 768 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $15,198.72. Following the completion of the sale, the executive directly owned 26,933 shares of the company’s stock, valued at $533,004.07. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CeriBell Stock Down 0.5%

CeriBell stock traded down $0.09 during trading hours on Thursday, hitting $18.86. The company had a trading volume of 143,858 shares, compared to its average volume of 345,803. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $25.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The firm has a market capitalization of $699.71 million, a P/E ratio of -12.83 and a beta of 1.03. The firm’s fifty day moving average is $21.20 and its 200-day moving average is $16.19.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 30.99%. The company had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. On average, research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on EPS and revenue — CeriBell reported Q4 EPS of ($0.36) vs. a consensus of ($0.43) and revenue of $24.78M vs. $23.95M expected, a beat that supports the recent uptick in the share price. MarketBeat: Q4 Results & Conference Call
• Positive Sentiment: FY‑2026 revenue guidance provided — Management gave revenue guidance of roughly $111M–$115M for FY‑2026, which is close to consensus (~$112.7M), offering a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call highlighted revenue surge and market expansion — Management commentary and the call transcript emphasized accelerating revenue and expansion into new markets, supporting upside potential if execution continues. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data appears unreliable this cycle — the published short‑interest entry shows zero shares / NaN change, which is likely a reporting artifact and provides no actionable signal today.
• Negative Sentiment: Multiple insider sales disclosed — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold small amounts of stock at roughly $19.79–$19.98, reducing their positions by fractions of a percent; while sizes are modest relative to total holdings, clustered insider selling can create short‑term investor concern. InsiderTrades: Xingjuan Chao Sale SEC Filing: CEO Ownership

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. lowered their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. TD Cowen reissued a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group lifted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CBLL. Russell Investments Group Ltd. grew its position in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after buying an additional 1,256 shares during the period. Deutsche Bank AG increased its position in CeriBell by 1.7% during the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after acquiring an additional 1,393 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of CeriBell by 10.8% during the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.